Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Common Equity: 2024

Historic Common Equity for Kura Oncology (KURA) over the last 1 years, with Dec 2024 value amounting to $413.6 million.

  • Kura Oncology's Common Equity fell 42.77% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year decrease of 42.77%. This contributed to the annual value of $413.6 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Common Equity amounted to $413.6 million in FY2024.
  • In the past 5 years, Kura Oncology's Common Equity registered a high of $413.6 million during FY2024, and its lowest value of $413.6 million during FY2024.
  • Moreover, its 1-year median value for Common Equity was $413.6 million (2024), whereas its average is $413.6 million.